Last updated on November 2017

A Phase III randomized, placebo-controlled, double-blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus Placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC)


Brief description of study

A Phase III randomized, placebo-controlled, double-blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus Placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC)

Detailed Study Description

This is a randomized trial to evaluate the clinical benefit of sorafenib 400 mg twice daily and erlotinib 150 mg once a day versus sorafenib 400 mg twice daily and placebo erlotinib once daily in subjects with unresectable advanced or metastatic Child-Pugh A HCC. Patients who are candidates for potentially curative intervention (i.e. surgical resection or local ablation) are not eligible for this study.

For Study Locations, Click Here

Clinical Study Identifier: TX15681

Contact Investigators or Research Sites near you

Start Over

Research Center

Research Center
Additional Locations, XX Australia

Research Center

Research Center
Additional Locations, XX Austria

Research Center

Research Center
Additional Locations, XX Belgium

Research Center

Research Center
Additional Locations, XX Brazil

Research Center

Research Center
Additional Locations, XX Canada

Research Center

Research Center
Additional Locations, XX Chile

Research Center

Research Center
Additional Locations, XX China

Research Center

Research Center
Additional Locations, XX France

Research Center

Research Center
Additional Locations, XX Germany

Research Center

Research Center
Additional Locations, XX Greece

Research Center

Research Center
Additional Locations, XX Israel

Research Center

Research Center
Additional Locations, XX Italy

Research Center

Research Center
Additional Locations, XX Poland

Research Center

Research Center
Additional Locations, XX Russian Federation

Research Center

Research Center
Additional Locations, XX South Africa

Research Center

Research Center
Additional Locations, XX Spain

Research Center

Research Center
Additional Locations, XX United Kingdom

Research Center

Research Center
Additional Locations, CA USA

Research Center

Research Center
Additional Locations, FL USA

Research Center

Research Center
Additional Locations, GA USA

Research Center

Research Center
Additional Locations, IL USA

Research Center

Research Center
Additional Locations, KY USA

Research Center

Research Center
Additional Locations, LA USA

Research Center

Research Center
Additional Locations, MA USA

Research Center

Research Center
Additional Locations, MO USA

Research Center

Research Center
Additional Locations, NM USA

Research Center

Research Center
Additional Locations, NY USA

Research Center

Research Center
Additional Locations, NC USA

Research Center

Research Center
Additional Locations, PA USA

Research Center

Research Center
Additional Locations, TX USA

Research Center

Research Center
Additional Locations, VA USA

Research Center

Research Center
Additional Locations, WA USA

Research Center

Research Center
Additional Locations, XX Bulgaria

Research Center

Research Center
Additional Locations, XX Colombia

Research Center

Research Center
Additional Locations, XX Hong Kong

Research Center

Research Center
Additional Locations, XX Republic of Korea

Research Center

Research Center
Additional Locations, XX New Zealand

Research Center

Research Center
Additional Locations, XX Peru

Research Center

Research Center
Additional Locations, XX Singapore

Research Center

Research Center
Additional Locations, XX Taiwan

Research Center

Research Center
Additional Locations, DC USA

Research Center

Research Center
Additional Locations, HI USA

Research Center

Research Center
Additional Locations, KS USA

Research Center

Research Center
Additional Locations, MD USA

Research Center

Research Center
Additional Locations, MI USA

Research Center

Research Center
Additional Locations, MN USA

Research Center

Research Center
Additional Locations, OH USA